Enveric Biosciences Q2 net loss $6.4M; cost cuts extend runway into Q1 2024

Enveric Biosciences, Inc.

2023-Q2 EPS reported -$5.35

Net loss of $6.40M ($3.04 per share) vs $2.87M ($2.73) in Q2 2022.
Cash & equivalents $7.08M at June 30; net cash used in operations $4.47M.
Cost reduction plan announced to extend financial runway into Q1 2024.
Multiple USPTO Notices of Allowance for composition of matter claims covering EB-373, EVM201, and EVM301 Series.
On track to identify EVM301 Series lead candidate by year-end 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Enveric Biosciences, Inc. reported second quarter of 2023 ended June 30, 2023 results: net income $6.40 million, EPS $3.04.

Period: second quarter of 2023 ended June 30, 2023
Net income: $6.40 million
EPS: $3.04
Result: reported results

Exact text from the filing

Net loss attributable to shareholders was $6.40 million for the second quarter ended June 30, 2023, including $1.64 million in net non-cash expenses, with a basic and diluted loss per share of $3.04, as compared to a net loss of $2.87 million and non-cash income of $1.04 million, with primary and diluted loss per share of $2.73 per share for the quarter ended June 30, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Enveric Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-028048

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.